Peptron, Inc. (KOSDAQ:087010)

South Korea · Delayed Price · Currency is KRW

199,800

+32,800 (19.64%)

Jun 29, 2026, 3:30 PM KST

-2.54% (1Y)

Market Cap	4.66T -13.1%
Revenue (ttm)	5.98B +39.3%
Net Income	-16.62B
EPS	-715.21
Shares Out	23.32M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	255,278
Open	173,800
Previous Close	167,000
Day's Range	173,800 - 204,000
52-Week Range	160,000 - 392,500
Beta	0.56
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Peptron

Peptron, Inc. engages in the development of peptide-based medicines. The company’s technologies include long acting; and SmartDepot, an ultrasonic spray drying technology for the preparation of sustained release injectable microsphere formulation of drug. It develops PAb 001 for cancer therapy; SR-Exenatide (PT320) for Parkinson’s and other neurodegenerative disease; SR-Octreotide for the treatment of acromegaly; and Dernak filler for bioequivalence. Peptron, Inc. was founded in 1997 and is headquartered in Daejeon, South Korea. [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1997

Country South Korea

Stock Exchange KOSDAQ

Ticker Symbol 087010

Full Company Profile

Financial Performance

In 2025, Peptron's revenue was 5.63 billion, an increase of 78.76% compared to the previous year's 3.15 billion. Losses were -13.82 billion, -37.26% less than in 2024.

Financial Statements